Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants

  • Earl, Julie
  • Galindo-Pumariño, Cristina
  • Encinas, Jessica
  • Barreto, Emma|||0000-0002-0410-2261
  • Castillo, Maria E.
  • Pachón, Vanessa
  • Ferreiro, Reyes
  • Rodríguez Garrote, Mercedes|||0000-0003-0486-6760
  • González-Martínez, Silvia
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Diaz, Luis Robles
  • Chirivella-Gonzalez, Isabel
  • Rodriguez, Montse
  • Martínez de Castro, Eva|||0000-0002-5772-0741
  • García-Seisdedos, David
  • Muñoz, Gloria
  • Rosa, Juan Manuel Rosa
  • Marquez, Mirari
  • Malats, Núria|||0000-0003-2538-3784
  • Carrato, Alfredo|||0000-0001-7749-8140
The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is around 5% due to the fact that the majority of patients present with advanced disease that is treatment resistant. Familial pancreatic cancer (FPC) is a rare disorder that is defined as a family with at least two affected first degree relatives, with an estimated incidence of 4%-10%. The genetic basis is unknown in the majority of families although around 10%-13% of families carry germline mutations in known genes associated with hereditary cancer and pancreatitis syndromes. Panel sequencing was performed of 35 genes associated with hereditary cancer in 43 PDAC cases from families with an apparent hereditary pancreatic cancer syndrome. Pathogenic variants were identified in 19% (5/26) of PDAC cases from pure FPC families in the genes MLH1, CDKN2A, POLQ and FANCM. Low frequency potentially pathogenic VUS were also identified in 35% (9/26) of PDAC cases from FPC families in the genes FANCC, MLH1, PMS2, CFTR, APC and MUTYH. Furthermore, an important proportion of PDAC cases harboured more than one pathogenic, likely pathogenic or potentially pathogenic VUS, highlighting the multigene phenotype of FPC. The genetic basis of familial or hereditary pancreatic cancer can be explained in 21% of families by previously described hereditary cancer genes. Low frequency variants in other DNA repair genes are also present in 35% of families which may contribute to the risk of pancreatic cancer development. This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I + D + i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/1034) and co-financed by the European Development Regional Fund ''A way to achieve Europe'' (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073) and La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A faecal microbiota signature with high specificity for pancreatic cancer

  • Kartal, Ece|||0000-0002-7720-455X
  • Schmidt, Thomas S B.|||0000-0001-8587-4177
  • Molina Montes, Esther|||0000-0002-0428-2426
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Wirbel, Jakob|||0000-0002-4073-3562
  • Maistrenko, Oleksandr M.|||0000-0003-1961-7548
  • Akanni, Wasiu A.|||0000-0002-2075-2387
  • Alashkar Alhamwe, Bilal|||0000-0002-7120-0013
  • Alves, Renato J.|||0000-0002-7212-0234
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Erasmus, Hans Peter
  • Estudillo, Lidia|||0000-0003-3891-3713
  • Finkelmeier, Fabian
  • Fullam, Anthony|||0000-0002-0884-8124
  • Glazek, Anna M.
  • Gómez-Rubio, Paulina
  • Hercog, Rajna
  • Jung, Ferris|||0000-0002-5534-7832
  • Kandels, Stefanie|||0000-0002-4194-4927
  • Kersting, Stephan|||0000-0002-2124-3103
  • Langheinrich, Melanie|||0000-0002-0120-9135
  • Márquez, Mirari
  • Molero, Xavier|||0000-0003-2473-7405
  • Orakov, Askarbek|||0000-0001-6823-5269
  • Van Rossum, Thea|||0000-0002-3598-5001
  • Torres, Raul|||0000-0001-9606-0398
  • Telzerow, Anja|||0000-0001-9855-0809
  • Zych, Konrad|||0000-0001-7426-0516
  • Benes, Vladimir|||0000-0002-0352-2547
  • Zeller, Georg|||0000-0003-1429-7485
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Real, Francisco X.|||0000-0001-9501-498X
  • Malats, Núria|||0000-0003-2538-3784
  • Bork, Peer|||0000-0002-2627-833X
  • Ilzarbe, Lucas|||0000-0003-1798-6876
  • Alvarez-Urturi, Cristina|||0000-0002-7305-9973
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Bory, Felipe
  • Márquez Mosquera, Lucía|||0000-0002-3182-9570
  • Poves, Ignasi
  • Burdío, Fernando|||0000-0003-3038-0086
  • Grande, L.|||0000-0001-9146-9004
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Guarner, Luisa
  • Balcells, Joaquin
  • Salcedo, Mayte
  • Farré, Antoni|||0000-0003-1279-8868
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Martín Flix, Marta|||0000-0001-7849-3616
  • Artigas Raventos, Vicens|||0000-0002-2874-2490
  • Guarner, Carlos|||0000-0001-5957-9481
  • Sancho, Francesc J.
  • Concepción, Mar|||0000-0003-1821-0359
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. To explore the faecal and salivary microbiota as potential diagnostic biomarkers. We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case-control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case-control study (n=76), in the validation phase. Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19-9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible.